Cara Therapeutics Inc. (CARA) 22.92 $CARA
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Aug 04, 3:02PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the closing of its underwritten public offering of 4,327,956 shares of its common stock at a public offering price of $18.60 per share, which included 564,516 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $80.5 million.
CARA: 22.92 (+0.80)
Cara Therapeutics to Announce Second Quarter 2015 Financial Results on August 10, 2015
GlobeNewswire - Mon Aug 03, 3:30PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2015, at 4:30 p.m. ET to report second quarter 2015 financial results and provide a corporate update.
CARA: 22.92 (+0.80)
An Encouraging Turn in the Study - Report on Cara Therapeutics Inc.
PR Newswire - Fri Jul 31, 8:20AM CDT
ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ: CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
CARA: 22.92 (+0.80)
Cara Therapeutics prices public offering at USD18.60 per share
M2 - Thu Jul 30, 3:05AM CDT
Biopharmaceutical company Cara Therapeutics (Nasdaq:CARA) said on Wednesday that it has priced a public offering of 3,763,440 shares of its common stock.
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
GlobeNewswire - Wed Jul 29, 6:10PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 3,763,440 shares of its common stock at a public offering price of $18.60 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $70 million. In addition, Cara Therapeutics granted the underwriters a 30-day option to purchase up to 564,516 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Cara Therapeutics.
CARA: 22.92 (+0.80)
Cara Therapeutics anticipates up to USD65m from public offering
M2 - Tue Jul 28, 4:09AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) stated on Monday that it expects up to USD65m from a planned public offering of shares of its common stock.
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Proposed Offering of Common Stock
GlobeNewswire - Mon Jul 27, 3:20PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it has commenced an underwritten public offering of shares of its common stock of up to $65 million. In addition, Cara Therapeutics expects to grant the underwriters a 30-day option to purchase an additional 15% of the number of shares of common stock sold on the same terms and conditions. All of the shares in the offering will be sold by Cara Therapeutics.
CARA: 22.92 (+0.80)
Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 7:51AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose roughly 8% on the day.
CARA: 22.92 (+0.80), AMAG: 69.36 (+2.26)
Why Cara Therapeutics Shares Are Soaring 30% Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 23, 11:20AM CDT
What: Shares in Cara Therapeutics are surging higher by 30% today after the company reported that its lead product candidate CR845 met its primary endpoint in a mid stage trial. So what: Cara Therapeutics is developing CR845 as a treatment...
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus
GlobeNewswire - Thu Jul 23, 6:00AM CDT
Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
CARA: 22.92 (+0.80)
Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics' CR845
PR Newswire - Tue Jul 14, 11:51AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that it has entered into a new agreement for continued clinical testing with development partner Cara Therapeutics (Nasdaq: CARA) involving Cara's peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.
CARA: 22.92 (+0.80)
3 Marijuana Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Fri Jul 10, 10:41AM CDT
Source: United States Fish and Wildlife Service. Here's a recipe for investing disaster: Buy penny stocks in a new market that many are claiming will soar in the next few years. Unfortunately, some could be headed for such a disaster with marijuana...
CARA: 22.92 (+0.80), INSY: 44.74 (-0.03), GWPH: 114.26 (+1.74)
Commit To Buy Cara Therapeutics At $10, Earn 34.5% Annualized Using Options
StockOptionsChannel.com - Thu Jun 25, 10:30AM CDT
Investors eyeing a purchase of Cara Therapeutics Inc stock, but cautious about paying the going market price of $12.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
CARA: 22.92 (+0.80)
Cara Therapeutics concludes patient admission under Phase 2 Trial of I.V. CR845 for treating uremic pruritus
M2 - Wed Jun 24, 3:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) said on Tuesday that it has closed enrolment under its Phase 2 proof-of-concept trial of CR845 for the treatment of uremic pruritus (UP), a chronic systemic itch condition that can occur in patients with renal failure and is often seen in patients receiving hemodialysis.
CARA: 22.92 (+0.80)
Cara Therapeutics hits enrollment target in mid-stage study of lead product candidate
Seeking Alpha - at Seeking Alpha - Tue Jun 23, 10:34AM CDT
CARA: 22.92 (+0.80)
Cara Therapeutics to Sponsor Symposium and Present Poster at the College on Problems of Drug Dependence 77th Annual Meeting
GlobeNewswire - Wed Jun 10, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a symposium titled "New Analgesic and Abuse Deterrent Approaches: Kappa Opioid Receptor Agonists (KORAs)" at the College on Problems of Drug Dependence (CPDD) 77 Annual Meeting in Phoenix, Arizona. Leading pain experts will discuss the latest developments in analgesia, including data from Cara's Phase 2 trial and human abuse liability study of CR845, the Company's first-in-class peripherally-selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
CARA: 22.92 (+0.80)
Cara Therapeutics to Present at the 2015 International Conference on Opioids
GlobeNewswire - Fri Jun 05, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief Medical Officer Dr. Joseph Stauffer will present data from the Company's human abuse liability study of I.V. CR845 during a poster session at the International Conference on Opioids (ICOO 2015), being held June 7-9 in Boston, MA. CR845 is Cara's first-in-class peripherally-selective kappa opioid receptor agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
CARA: 22.92 (+0.80)
Retail Layoffs Highlight Opportunity in the Cannabis Space
ACCESSWIRE - Tue May 19, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / May 19, 2015 / On May 14, 2015, Shawn Phillips, owner of nine cannabis stores in Colorado, announced he had laid off 65 of his employees, accounting for approximately 45% of the company's total workforce. The stores are all part of a wider brand network called Strainwise, which currently operates 13 stores in Colorado, and sells marijuana both to recreational and medicinal users.
CARA: 22.92 (+0.80)
Cara Therapeutics reports Q1 results
Seeking Alpha - at Seeking Alpha - Wed May 13, 8:17AM CDT
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Aug 04, 3:02PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the closing of its underwritten public offering of 4,327,956 shares of its common stock at a public offering price of $18.60 per share, which included 564,516 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $80.5 million.
CARA: 22.92 (+0.80)
Cara Therapeutics to Announce Second Quarter 2015 Financial Results on August 10, 2015
GlobeNewswire - Mon Aug 03, 3:30PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2015, at 4:30 p.m. ET to report second quarter 2015 financial results and provide a corporate update.
CARA: 22.92 (+0.80)
An Encouraging Turn in the Study - Report on Cara Therapeutics Inc.
PR Newswire - Fri Jul 31, 8:20AM CDT
ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ: CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
CARA: 22.92 (+0.80)
Cara Therapeutics prices public offering at USD18.60 per share
M2 - Thu Jul 30, 3:05AM CDT
Biopharmaceutical company Cara Therapeutics (Nasdaq:CARA) said on Wednesday that it has priced a public offering of 3,763,440 shares of its common stock.
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
GlobeNewswire - Wed Jul 29, 6:10PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 3,763,440 shares of its common stock at a public offering price of $18.60 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $70 million. In addition, Cara Therapeutics granted the underwriters a 30-day option to purchase up to 564,516 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Cara Therapeutics.
CARA: 22.92 (+0.80)
Cara Therapeutics anticipates up to USD65m from public offering
M2 - Tue Jul 28, 4:09AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) stated on Monday that it expects up to USD65m from a planned public offering of shares of its common stock.
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Proposed Offering of Common Stock
GlobeNewswire - Mon Jul 27, 3:20PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it has commenced an underwritten public offering of shares of its common stock of up to $65 million. In addition, Cara Therapeutics expects to grant the underwriters a 30-day option to purchase an additional 15% of the number of shares of common stock sold on the same terms and conditions. All of the shares in the offering will be sold by Cara Therapeutics.
CARA: 22.92 (+0.80)
Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 7:51AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose roughly 8% on the day.
CARA: 22.92 (+0.80), AMAG: 69.36 (+2.26)
Why Cara Therapeutics Shares Are Soaring 30% Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 23, 11:20AM CDT
What: Shares in Cara Therapeutics are surging higher by 30% today after the company reported that its lead product candidate CR845 met its primary endpoint in a mid stage trial. So what: Cara Therapeutics is developing CR845 as a treatment...
CARA: 22.92 (+0.80)
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus
GlobeNewswire - Thu Jul 23, 6:00AM CDT
Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
CARA: 22.92 (+0.80)
Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics' CR845
PR Newswire - Tue Jul 14, 11:51AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that it has entered into a new agreement for continued clinical testing with development partner Cara Therapeutics (Nasdaq: CARA) involving Cara's peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.
CARA: 22.92 (+0.80)
3 Marijuana Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Fri Jul 10, 10:41AM CDT
Source: United States Fish and Wildlife Service. Here's a recipe for investing disaster: Buy penny stocks in a new market that many are claiming will soar in the next few years. Unfortunately, some could be headed for such a disaster with marijuana...
CARA: 22.92 (+0.80), INSY: 44.74 (-0.03), GWPH: 114.26 (+1.74)
Commit To Buy Cara Therapeutics At $10, Earn 34.5% Annualized Using Options
StockOptionsChannel.com - Thu Jun 25, 10:30AM CDT
Investors eyeing a purchase of Cara Therapeutics Inc stock, but cautious about paying the going market price of $12.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
CARA: 22.92 (+0.80)
Cara Therapeutics concludes patient admission under Phase 2 Trial of I.V. CR845 for treating uremic pruritus
M2 - Wed Jun 24, 3:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) said on Tuesday that it has closed enrolment under its Phase 2 proof-of-concept trial of CR845 for the treatment of uremic pruritus (UP), a chronic systemic itch condition that can occur in patients with renal failure and is often seen in patients receiving hemodialysis.
CARA: 22.92 (+0.80)
Cara Therapeutics hits enrollment target in mid-stage study of lead product candidate
Seeking Alpha - at Seeking Alpha - Tue Jun 23, 10:34AM CDT
CARA: 22.92 (+0.80)
Cara Therapeutics to Sponsor Symposium and Present Poster at the College on Problems of Drug Dependence 77th Annual Meeting
GlobeNewswire - Wed Jun 10, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it will sponsor a symposium titled "New Analgesic and Abuse Deterrent Approaches: Kappa Opioid Receptor Agonists (KORAs)" at the College on Problems of Drug Dependence (CPDD) 77 Annual Meeting in Phoenix, Arizona. Leading pain experts will discuss the latest developments in analgesia, including data from Cara's Phase 2 trial and human abuse liability study of CR845, the Company's first-in-class peripherally-selective kappa opioid agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
CARA: 22.92 (+0.80)
Cara Therapeutics to Present at the 2015 International Conference on Opioids
GlobeNewswire - Fri Jun 05, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Chief Medical Officer Dr. Joseph Stauffer will present data from the Company's human abuse liability study of I.V. CR845 during a poster session at the International Conference on Opioids (ICOO 2015), being held June 7-9 in Boston, MA. CR845 is Cara's first-in-class peripherally-selective kappa opioid receptor agonist, which has potential to be the only Schedule V or non-scheduled opioid for acute pain.
CARA: 22.92 (+0.80)
Retail Layoffs Highlight Opportunity in the Cannabis Space
ACCESSWIRE - Tue May 19, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / May 19, 2015 / On May 14, 2015, Shawn Phillips, owner of nine cannabis stores in Colorado, announced he had laid off 65 of his employees, accounting for approximately 45% of the company's total workforce. The stores are all part of a wider brand network called Strainwise, which currently operates 13 stores in Colorado, and sells marijuana both to recreational and medicinal users.
CARA: 22.92 (+0.80)
Cara Therapeutics reports Q1 results
Seeking Alpha - at Seeking Alpha - Wed May 13, 8:17AM CDT
CARA: 22.92 (+0.80)
